HC Wainwright Brokers Reduce Earnings Estimates for NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at HC Wainwright cut their Q1 2026 earnings per share estimates for shares of Intellia Therapeutics in a report released on Monday, March 2nd. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.97) per share for the quarter, down from their prior estimate of ($0.93). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.71) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business had revenue of $23.02 million for the quarter, compared to the consensus estimate of $12.17 million. During the same period in the previous year, the business earned ($1.27) earnings per share. The business’s revenue was up 78.4% on a year-over-year basis.

NTLA has been the subject of a number of other reports. Wells Fargo & Company increased their price objective on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday. Brookline Capital Acquisition restated a “buy” rating on shares of Intellia Therapeutics in a research report on Tuesday. Citizens Jmp lifted their price target on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the company a “market outperform” rating in a report on Tuesday. JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research note on Wednesday. Finally, Bank of America reissued a “neutral” rating on shares of Intellia Therapeutics in a report on Monday. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $19.59.

Intellia Therapeutics Trading Down 4.8%

Shares of NTLA opened at $13.15 on Wednesday. The business’s 50 day moving average is $12.25 and its 200 day moving average is $13.10. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.25. The company has a market capitalization of $1.55 billion, a PE ratio of -3.43 and a beta of 2.10.

Insiders Place Their Bets

In related news, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the completion of the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John M. Leonard sold 34,146 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the completion of the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at approximately $9,332,852.19. This represents a 3.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 53,051 shares of company stock valued at $488,600 in the last three months. Corporate insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in shares of Intellia Therapeutics in the second quarter valued at approximately $26,000. Comerica Bank increased its stake in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the period. Blue Bell Private Wealth Management LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Finally, Advisory Services Network LLC purchased a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $33,000. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene‑therapy trial for Intellia — a material de‑risking event that restores clinical momentum for NTLA’s in‑vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near‑term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near‑term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near‑term cost pressure acknowledged, long‑term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near‑term sentiment and give holders a reason to take profits after the run‑up. Canaccord lowers expectations

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.